Switch theme
Sign up to access all valuation multiples
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
1942
81K+
LTM Revenue $63.4B
LTM EBITDA $24.4B
$172B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pfizer has a last 12-month revenue of $63.4B and a last 12-month EBITDA of $24.4B.
In the most recent fiscal year, Pfizer achieved revenue of $63.6B and an EBITDA of $18.1B.
Pfizer expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pfizer valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $58.5B | $63.6B | XXX | XXX | XXX |
| Gross Profit | $66.0B | $33.5B | XXX | XXX | XXX |
| Gross Margin | 113% | 53% | XXX | XXX | XXX |
| EBITDA | $9.6B | $18.1B | XXX | XXX | XXX |
| EBITDA Margin | 16% | 28% | XXX | XXX | XXX |
| Net Profit | $31.4B | $2.1B | XXX | XXX | XXX |
| Net Margin | 54% | 3% | XXX | XXX | XXX |
| Net Debt | $34.5B | $68.0B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 25, 2025, Pfizer's stock price is $23.
Pfizer has current market cap of $129B, and EV of $172B.
See Pfizer trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $172B | $129B | XXX | XXX | XXX | XXX | $3.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 25, 2025, Pfizer has market cap of $129B and EV of $172B.
Pfizer's trades at 2.7x LTM EV/Revenue multiple, and 7.1x LTM EBITDA.
Analysts estimate Pfizer's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Pfizer and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $172B | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.5x | XXX | XXX | XXX |
| P/E | 16.1x | XXX | XXX | XXX |
| P/E/Growth | 0.3x | XXX | XXX | XXX |
| EV/FCF | 17.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPfizer's NTM/LTM revenue growth is -1%
Pfizer's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Pfizer's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Pfizer's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Pfizer and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 90% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 27% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 48% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pfizer acquired XXX companies to date.
Last acquisition by Pfizer was XXXXXXXX, XXXXX XXXXX XXXXXX . Pfizer acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Pfizer founded? | Pfizer was founded in 1942. |
| Where is Pfizer headquartered? | Pfizer is headquartered in United States of America. |
| How many employees does Pfizer have? | As of today, Pfizer has 81K+ employees. |
| Who is the CEO of Pfizer? | Pfizer's CEO is Dr. Albert Bourla, D.V.M.,PhD. |
| Is Pfizer publicy listed? | Yes, Pfizer is a public company listed on NYS. |
| What is the stock symbol of Pfizer? | Pfizer trades under PFE ticker. |
| When did Pfizer go public? | Pfizer went public in 1951. |
| Who are competitors of Pfizer? | Similar companies to Pfizer include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Pfizer? | Pfizer's current market cap is $129B |
| What is the current revenue of Pfizer? | Pfizer's last 12-month revenue is $63.4B. |
| What is the current EBITDA of Pfizer? | Pfizer's last 12-month EBITDA is $24.4B. |
| What is the current EV/Revenue multiple of Pfizer? | Current revenue multiple of Pfizer is 2.7x. |
| What is the current EV/EBITDA multiple of Pfizer? | Current EBITDA multiple of Pfizer is 7.1x. |
| What is the current revenue growth of Pfizer? | Pfizer revenue growth between 2023 and 2024 was 9%. |
| Is Pfizer profitable? | Yes, Pfizer is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
